Celadon Pharmaceuticals Plc (AIM: CEL)

Market Cap	10.33M
Revenue (ttm)	130.00K
Net Income (ttm)	-5.23M
Shares Out	68.85M
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	44,433
Open	17.76
Previous Close	16.50
Day's Range	15.26 - 19.00
52-Week Range	11.00 - 122.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 27, 2024

About Celadon Pharmaceuticals

Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products. Its products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2018
• Employees: 27
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: CEL

Financial Performance

In 2023, Celadon Pharmaceuticals's revenue was 75,000, an increase of 212.50% compared to the previous year's 24,000. Losses were -7.14 million, -58.01% less than in 2022.